01
The Condition
Understanding Osteoarthritis
Osteoarthritis (OA) is a chronic, progressive joint disease characterised by the breakdown of articular cartilage — the smooth, protective tissue covering the ends of bones. As cartilage deteriorates, bones may begin to rub against each other, leading to pain, stiffness, swelling, and eventually reduced function. Contrary to older beliefs, OA is not simply "wear and tear" — it involves complex biochemical and mechanical changes affecting the entire joint, including cartilage, bone, synovium, ligaments, and surrounding muscles.
OA is the most common form of arthritis globally, affecting over 500 million people. The knee, hip, and hand joints are most commonly affected. While age is the strongest risk factor, OA is not an inevitable consequence of ageing — and its progression can be meaningfully slowed, and symptoms substantially relieved, without surgery.
🔑
The key insight
OA severity on imaging does not reliably predict pain or disability. Many people with significant radiographic changes have little pain, while others with mild X-ray changes experience significant symptoms. This is why management must be tailored to the patient, not the scan — and why non-surgical strategies are effective even in moderate-to-severe imaging grades.
Myth
"Once cartilage is gone, nothing can help without surgery."
Multiple non-surgical therapies reduce pain, improve function, and slow progression — independent of the degree of cartilage loss visible on imaging.
Fact
Exercise is the single most evidence-backed intervention for OA pain.
Structured exercise consistently outperforms analgesic medications and anti-inflammatories in head-to-head trials for knee and hip OA, with a superior safety profile and durable benefits.
Myth
"Exercise will damage my joints further."
This is one of the most harmful misconceptions in OA care. Appropriate, supervised exercise strengthens periarticular muscle, reduces joint load, and is associated with cartilage preservation, not damage.
Fact
Most OA patients are not surgical candidates — nor do they need to be.
Clinical guidelines from OARSI, EULAR, and NICE all position joint replacement as a late-stage option after structured non-surgical management has been optimised over at least 3–6 months.
02
First-Line Therapy
Physiotherapy & Exercise Therapy
Exercise therapy is the cornerstone of OA management. It is recommended first-line by every major international guideline and has the strongest evidence base of any non-pharmacological intervention. The goal is not to "work through" pain, but to progressively load the joint in a way that builds muscle strength, improves neuromuscular control, and reduces joint stress.
An effective programme typically combines three elements: strengthening (targeting quadriceps, hip abductors, and core), aerobic conditioning (low-impact activities such as cycling, swimming, or walking), and flexibility and balance training. Research shows that a 6–12 week supervised programme reduces pain by 30–50% and improves function comparably to NSAID therapy.
💪
Strengthening
Quad sets, leg press, hip abductor exercises. 2–3 sessions per week. Progressive resistance is key — not high impact.
🚴
Aerobic Conditioning
Cycling, swimming, aquatic therapy, or walking. 150 minutes per week of moderate activity reduces OA progression risk.
🧘
Balance & Flexibility
Proprioception training, yoga-based stretching, and foam rolling reduce fall risk and improve functional ROM.
📋
Aquatic therapy — an underused gem
Water-based exercise provides resistance without joint load. For patients with significant pain on weight-bearing, hydrotherapy allows early therapeutic exercise that would otherwise be impossible. Evidence supports its effectiveness in both knee and hip OA, particularly in the early rehabilitation phase.
If exercise were a pill, it would be the most prescribed drug in the world for arthritis. The challenge is not evidence — it's delivering it in a way that patients can sustain.
Dr. Sarish Sharma · Joint Preservation Specialist
03
Intra-Articular Therapies
Injections — what works and for whom
Intra-articular (into-the-joint) injections can provide meaningful relief, particularly when exercise alone is insufficient, or as a bridge while building strength. The three main options — corticosteroids, hyaluronic acid (viscosupplementation), and platelet-rich plasma (PRP) — differ significantly in mechanism, duration of effect, and evidence quality.
Anti-inflammatory injection providing fast pain relief. Onset within 48–72 hours. Typically lasts 4–8 weeks. Best for acute flares with joint effusion. Repeated injections may accelerate cartilage loss — limit to 3–4 per year per joint.
Pain relief duration
Hyaluronic acid injection restores joint lubrication. Slower onset (2–4 weeks) but longer duration — 3–6 months in responders. Most effective in mild-to-moderate knee OA. Less evidence for hip. Single or multi-injection protocols available.
Pain relief duration
Concentrated growth factors from the patient's own blood. Promotes cartilage repair and reduces inflammation. Duration 6–12+ months in responders. Growing evidence base, particularly for early-to-moderate OA. No risk of allergy (autologous).
Pain relief duration
| Injection |
Onset |
Best for |
Evidence level |
Cautions |
| Corticosteroid |
48–72 hrs |
Acute flare, effusion |
|
Limit frequency; risk of cartilage loss |
| Hyaluronic Acid |
2–4 weeks |
Mild–moderate knee OA |
|
Variable response; less evidence in hip |
| PRP |
2–6 weeks |
Early–moderate OA; younger patients |
|
Cost; variability in PRP preparation |
| Stem Cell |
4–12 weeks |
Investigational; early OA |
|
Limited long-term data; high cost |
04
Lifestyle Optimisation
Weight, Diet & Lifestyle — the multiplier effect
Non-pharmacological lifestyle changes are among the most powerful and durable tools available — yet they are consistently under-utilised in clinical practice. Every kilogram of body weight lost translates to approximately 4 kg of reduced knee joint load with each step taken. A 10% reduction in body weight can reduce knee OA pain by up to 50% in overweight patients — comparable to surgical outcomes in some studies.
Diet plays a dual role: caloric deficit for weight management, and anti-inflammatory dietary patterns that may directly modulate OA-related inflammation. The Mediterranean diet, rich in omega-3 fatty acids, polyphenols, and antioxidants, has the strongest evidence for reducing systemic inflammation associated with OA.
⚖️
Weight Management
Evidence: High
Even modest weight loss (5–10% body weight) produces significant pain reduction. Structured programmes combining dietary advice and supervised exercise are most effective. Every 1 kg lost = 4 kg less knee load.
🥗
Mediterranean Diet
Evidence: Moderate
Rich in olive oil, oily fish, legumes, vegetables, and nuts. Associated with lower OA progression, reduced systemic inflammation (CRP), and improved pain scores in cohort studies.
😴
Sleep Optimisation
Evidence: Moderate
Poor sleep amplifies pain perception and is associated with faster OA progression. Addressing sleep hygiene, treating sleep apnoea, and CBT-I for insomnia all reduce pain scores independently of other interventions.
🧘
Mind-Body Approaches
Evidence: Moderate
Mindfulness-based stress reduction (MBSR), cognitive behavioural therapy (CBT), and pain education programmes all reduce pain catastrophising — a major driver of disability in OA independent of structural severity.
🦯
Bracing, orthotics & walking aids
Medial unloader braces (for medial compartment knee OA), lateral wedge insoles, and custom foot orthotics can meaningfully redistribute joint load and reduce pain. Walking aids, when correctly prescribed, reduce joint stress — using a stick in the contralateral hand reduces hip joint load by up to 30%. These are underused tools that require no recovery time and carry no risk.
05
Pharmacological Support
Medications & Supplements — an honest review
Medications play a supportive role in OA management — they do not modify disease course but can help manage symptoms sufficiently to enable exercise and maintain function. The hierarchy of pharmaceutical options moves from topical to oral to injectable, prioritising the safest effective option for each patient.
🩹
Topical NSAIDs
Evidence: High
Topical diclofenac gel or ketoprofen — effective for knee and hand OA with substantially fewer systemic side effects than oral NSAIDs. Preferred first pharmacological option per NICE and OARSI guidelines.
💊
Oral NSAIDs
Evidence: High (short-term)
Effective for pain control but associated with GI, cardiovascular, and renal risks with long-term use. Use the lowest effective dose for the shortest necessary duration, with gastroprotection in high-risk patients.
🧬
Duloxetine
Evidence: Moderate
An SNRI antidepressant with NICE-approved OA pain indication. Useful for patients with central sensitisation features — widespread pain, poor sleep, anxiety — where peripheral-only approaches underperform.
🌿
Glucosamine / Chondroitin
Evidence: Contested
Some meta-analyses show benefit; others show no effect beyond placebo. OARSI currently rates as "uncertain." A subset of patients (particularly those with moderate-to-severe knee OA) appear to respond. Safe to trial for 3 months; continue only if benefit is perceived.
⚠️
What to avoid
Long-term opioid therapy for OA is not recommended — evidence shows limited long-term benefit and significant harms (dependence, falls, cognitive impairment). Paracetamol (acetaminophen) has been downgraded in major guidelines due to limited efficacy in OA and liver toxicity risk at higher doses. Its routine use is no longer recommended as first-line.
06
Decision Framework
When surgery does become the answer
Non-surgical management will not be indefinitely effective for all patients. There are clear clinical thresholds at which joint replacement or other surgical interventions become appropriate — and recognising these thresholds is as important as maximising conservative care before reaching them.
Step 1 — Months 1–3
Optimise conservative care
Structured physiotherapy programme (6–12 weeks), lifestyle modification, topical or oral NSAIDs where needed, weight management support. Most patients improve significantly at this stage.
Step 2 — Months 3–6
Consider intra-articular therapies
PRP or viscosupplementation for patients who have not achieved adequate relief with physiotherapy and medications. Corticosteroid for acute flares. Reassess function and symptom scores objectively (KOOS, HOOS).
Step 3 — Months 6–12
Specialist reassessment
If significant disability persists despite optimised non-surgical care, referral to an orthopaedic specialist for surgical planning is appropriate. At this stage, discussion of joint replacement, osteotomy, or arthroscopy depends on joint, age, and activity level.
Surgery — when indicated
Clear surgical thresholds
Surgery is appropriate when: pain severely limits daily function despite full conservative optimisation; there is significant deformity or instability; quality of life is substantially impaired; and the patient is medically fit for surgery. Age alone is not an exclusion criterion.
✅
The bottom line
Non-surgical management of OA is not a consolation prize while waiting for a joint replacement. It is the primary treatment for the majority of OA patients — effective, evidence-based, and capable of delivering lasting improvements in pain and function. The goal is to live well with the joint you have, for as long as possible, using every tool available.